

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
**WO 2004/052268 A1**

(51) International Patent Classification: A61J 1/00,  
A61M 1/28, B65D 81/32, A61K 9/08, 31/70

(21) International Application Number:  
PCT/SE2003/001920

(22) International Filing Date:  
10 December 2003 (10.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0203671-3 10 December 2002 (10.12.2002) SE  
60/432,580 10 December 2002 (10.12.2002) US

(71) Applicant (for all designated States except US): GAM-  
BRO LUNDIA AB [SE/SE]; Box 10101, S-220 10 Lund  
(SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CARLSSON,

Ola [SE/SE]; Skyttelinrjen 259, S-226 49 Lund (SE).  
LINDEN, Torbjörn [SE/SE]; Svensköpsvägen 110-4,  
SE-LINDERÖD (SE). WIESLANDER, Anders [SE/SE];  
Väpplingevägen 17 A, S-222 38 Lund (SE).


(74) Agent: AWAPATENT AB; Box 5117, SE-200 71 Malmö  
(SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO,  
CR, CU, CZ (utility model), CZ, DE (utility model), DE,  
DK (utility model), DK, DM, DZ, EC, EE (utility model),  
EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,  
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,

(Continued on next page)

(54) Title: A METHOD FOR PREPARING A MEDICAL SOLUTION FOR THE MANUFACTURE OF A MEDICAMENT FOR PERITONEAL DIALYSIS



Inhibition of cell-growth in a solution containing 1.5% NAG.

(57) Abstract: Method for preparing a medical solution, comprising the steps of a) providing a solution comprising one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH from 2.5 to 5.0, and b) terminal sterilisation of said at least one compartment and the contents therein, is disclosed, as well as a solution used for preparing the medical solution, a container-containing said solution, and use of said solution for the manufacture of a medicament for peritoneal dialysis.



SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *with international search report*

A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis.

### Background of the Invention

The present invention relates to a method for preparing a medical solution, a solution used for preparing the medical solution, a container containing said solution, and use of said solution for the manufacture of a medicament for peritoneal dialysis.

### Background Art

N-acetylglucosamine (NAG) and glucosamine are biochemically classified as amino sugars. Amino sugars are formed in almost all cells from blood glucose through a series of biochemical reactions. Hyaluronan is a polymer composed of dimers containing N-acetylglucosamine and glucuronic acid. It has been shown that the function of the peritoneum as a dialysis membrane is better preserved in rats that have been chronically dialyzed with fluid supplemented with exogenous hyaluronan (see Wieczorowska K, Breborowicz A et al, Protective effect of hyaluronic acid against peritoneal injury, Perit Dial Int 1995; 15:81-83).

Breborowicz A, Kuzlan-Pawlaczyk M et al, The Effect of N-Acetyl-glucosamine as a Substrate for In Vitro Synthesis of Glycosaminoglycans by Human Peritoneal Mesothelial Cells and Fibroblasts, Advances in Peritoneal Dialysis, 1998; 14:31-35, teaches that NAG rapidly stimulates the production of hyaluronan and sulphated glycosaminoglycans by human peritoneal mesothelial cells and fibroblasts.

Wu G, Wieczorowska-Tobis K, et al, N-acetylglucosamine changes permeability of peritoneum during chronic peritoneal dialysis in rats, Perit Dial Int, 1998; 18:217-224 concludes that peritoneal dialysis with a dialysis solution supplemented with N-acetylglucosamine causes accumulation of glucosaminoglycans in the peri-

toneal interstitium, resulting in a favorable change of the peritoneal permeability.

Breborowicz, M et al discloses replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid.

U.S. patent No. 5,536,469 discloses a system employing a sterile medical solution containing glucose or glucose-like compounds and a solution intended for said system.

Due to its advantageous characteristics, NAG has been introduced as a component in peritoneal dialysis solutions replacing part or all of the glucose component with a view to obtaining a more biocompatible peritoneal dialysis solution (see WO97/06810).

Peritoneal dialysis is a method for exchanging solutes and water in capillary vessels of a patient's peritoneum with hypertonic solution, which is infused into the peritoneal cavity. The principle of this method is diffusion of solutes transferred according to the concentration gradient and water migration due to osmotic differences. This method has many advantages, e.g. that no special apparatus is commonly required. It gives less influence on the hemodynamics because extracorporeal circulation of the patient's blood is not necessary, and further the peritoneal dialysis is a continuous treatment and therefore more similar to the function of the kidneys.

Peritoneal dialysis is usually classified as continuous ambulatory peritoneal dialysis (CAPD), intermittent peritoneal dialysis (IPD), continuous cyclic peritoneal dialysis (CCPD) or automated peritoneal dialysis (APD).

In CAPD a catheter is permanently implanted in the abdominal wall of the patient and about 1.5 to 2.5 l of the dialysis fluid is normally introduced via the catheter into the peritoneal cavity. The peritoneal cavity is flooded with this fluid, left for an appropriate lapse of

time and then drained. Removal of solutes and water takes place across the peritoneum, which acts as a semipermeable membrane.

The dialysis fluid normally used for peritoneal dialysis is an aqueous solution comprising an osmotic agent such as glucose and the like, electrolytes such as sodium, potassium, calcium, magnesium, and organic acid salts such as sodium lactate, sodium bicarbonate, or sodium pyruvate. The components of these peritoneal dialysis fluids are selected to control the levels of electrolytes or the acid-base equilibrium, to remove waste materials and to efficiently carry out ultrafiltration.

It is known to pack medical solutions in multicompartment bags from e.g. WO 99/27885 (Gambro Lundia AB), in which different solutes may be kept in separate compartments of the bag with a view to, inter alia, regulating the concentration of active ingredients in the finally prepared solution.

Medical fluids are normally sterilised by heat. Medical authorities in many countries require sterilisation after final packaging of the medical product. It is therefore often not possible to sterile filter the solution.

However, a problem with the formation of undesired cytotoxic products during heat sterilisation and storage exists for a variety of medical solutions, inter alia within the dialysis area, e.g. for peritoneal dialysis solutions. It is known e.g. from EP-B1-0 668 785 (Gambro Lundia AB) to reduce the amount of toxic degradation products from glucose or glucose-like compounds in a medical solution.

It has now been found that also amino sugars, e.g. NAG, in conventional medical solutions exhibit an increased cytotoxicity after heat sterilisation. This cytotoxicity depends on the formation of toxic degradation products from said amino sugars. In contact to glucose, none of the known glucose degradation products has been

found in heat sterilised NAG solutions. This fact has not been known previously and forms the basis for the present invention.

5 NAG and other amino sugars have a major difference from glucose and glucose-like compounds by having one amino group and possibly an acetyl group coupled to the glucose ring. Regarding the degradation process, it has been found that the pH of a NAG solution increases during sterilisation while in the case of glucose it decreases  
10 during sterilisation. This indicates that NAG is, in contrast to glucose, degraded by a hydrolysis that forms acetate, which increases the pH.

Thus, there is a need to solve the above defined problem and to provide a medical solution containing  
15 amino sugars, in particular NAG, and derivatives thereof and at the same time having the ability to be heat sterilised without the formation of the above-mentioned cytotoxic products.

#### Summary of the Invention

20 The object of the present invention is to solve the above-mentioned problem.

According to the present invention this object is achieved by an improved method for preparing a medical solution, preferably a peritoneal dialysis solution, comprising the steps of:  
25

a) providing a solution comprising one or more acetylated or deacetylated amino sugars in at least one compartment of a container, said solution having a pH of 2.0-5.0, and

30 b) terminal sterilisation of said at least one compartment and the contents therein.

Further, the present invention relates to the solution used for preparing the medical solution, and to a container containing said solution.

35 The present invention also relates to use of said solution for the manufacture of a medicament for peritoneal dialysis.

In another aspect the present invention relates to a method of performing peritoneal dialysis, wherein said method comprises the introduction of said medicament for peritoneal dialysis into the peritoneal cavity of a patient.

Further disclosure of the objects, problems, solutions and features of the present invention will be apparent from the following detailed description of the invention with reference to the drawings and the appended claims.

#### Brief Description of the Drawings

Fig. 1 is a graph showing the relationship between pH and inhibition of cell growth (ICG) in a solution containing 1.5% NAG.

Fig. 2 is a bar diagram showing the effect of increased NAG concentration of 1.5% and 30% for three different pH values.

Fig. 3 is a graph showing the fluorescence of heat sterilised NAG containing solutions at different pH values.

Figs. 4a - 4d are HPLC chromatograms showing the different decomposition patterns between a heat sterilised NAG solution and a heat sterilised glucose solution.

#### Detailed Description of Preferred Embodiments

The present invention is a development of the above mentioned teachings and relates to a method for preparing a sterile medical solution, preferably a solution for peritoneal dialysis.

Experiments in which measurements of the percentage of inhibition of cell growth (ICG) and fluorescence have been made at varying pH values and NAG concentrations during terminal heat sterilisation are illustrated in Figs 1-3. The results of the experiments imply that the pH of the amino sugar containing solution should be decreased from the neutral level and that, in a preferred

embodiment of the invention, also the concentration of the amino sugar/sugars should be optimised.

A simple, reliable and known way to study the cytotoxicity of substances or of medical fluids is to test proliferation as in vitro inhibition of cell growth (ICG) in cultured cells. Another method to get a rough estimation of the amount of amino sugars that is rearranged is measurement of the fluorescence.

More precisely, from the graph in Fig. 1 it can be seen that the inhibition of cell growth reaches a minimum with sterilisation around pH 2.5-3.5 in a solution containing 1.5% NAG. This implies that a NAG containing solution sterilised at an optimal pH around 2.5-3.5 from an in vitro toxicological point of view is more compatible for humans than solutions giving a higher percentage of inhibited growth when sterilised at higher or lower pH values.

The bar diagram in Fig. 2 illustrates the effect of increased NAG concentration at different pH values during terminal heat sterilisation. It can be seen that the percentage inhibition of cell growth is lower after terminal heat sterilisation at a pH of 3.0 than at a pH of 5.5 and 7.2, and that the inhibition of cell growth is lower after a terminal heat sterilisation at a NAG concentration of 30% than at a NAG concentration of 1.5% for all three pH values.

Fig. 3 shows the relationship between pH for a terminally heat sterilised NAG containing solution and the fluorescence, measured at an excitation at 350 nm and an emission of 430 nm. The lowest fluorescence is seen at around pH 4, which corresponds well with the toxicity result shown in Fig. 1.

The term "terminal" sterilisation used herein is intended to mean that the product is sterilised in its final package by a sterilisation method involving addition of energy, e.g. heating and/or radiation (see also European Pharmacopoeia 1977, p 283, col 1, last para-



graph, to col 2, first paragraph, and p 284, col 2, "Filtration", for a detailed description of this term, as well as for a review of different sterilisation techniques). Sterile filtration involves filtration of the solution to be included in the product, and the solution is aseptically filled into the container. This does not secure the sterility required in this context, and sterile filtration can therefore not be used as a sterilisation method for a medicament if it is possible to sterilise the medicament by terminal sterilisation.

The terminal sterilisation may include heat sterilisation and/or radiation sterilisation, but is preferably heat sterilisation effected in an autoclave at a temperature of at least 100°C, preferably at 121°C. The sterilisation time may vary depending on the sterilisation temperature, the type of container and the contents therein to be sterilised. The radiation sterilisation may be either ionizing or non-ionizing sterilisation. Examples of ionising sterilisation are gamma and beta radiation. An example of non-ionizing radiation sterilisation is UV radiation.

The method according to the present invention is preferably effected for a multicompartment container as disclosed in WO 99/27885 (Gambro AB). In the present invention, such a container comprises at least one compartment containing a physiologically compatible pH adjusting and diluting solution as well as at least one compartment containing a solution comprising one or more acetylated or deacetylated amino sugars, in the following called amino sugar solution for simplicity. The amino sugar solution may be present in only one compartment. The solutions in the different compartments are heat sterilisable, and the whole container can be heat sterilised in an autoclave with the solutions in situ in said compartments. The solutions in the separated compartments, which are delimited from each other during the sterilisation and the subsequent storage, can be mixed after sterilisation.

tion to form a finally prepared sterile medical solution, preferably a solution for peritoneal dialysis. It may also be mixed with a terminally sterilised pH adjusting and diluting solution in at least one other terminally  
5 sterilised compartment of the container, thereby finally preparing the medical solution. Such a medical solution may be stored after terminal sterilisation up to longer periods of time before mixing with the terminally sterilised pH adjusting and diluting solution. The  
10 terminal sterilisation can however also be effected for separated interconnectable containers comprising the solutions to sterilise and provided with connection means with sterile connecting valves for sterile connection. The separated containers can also be connected already  
15 during manufacture by means of a breakable seal, for example a conventional frangible pin.

According to the invention, the pH of the amino sugar containing solution is 2.0-5.0. In one preferred embodiment of the invention the pH of the amino sugar  
20 containing solution is preferably 2.5-3.5, most preferably 3.0, so that the formation of cytotoxic substances during the terminal sterilisation step is substantially prevented.

In another embodiment of the invention the amino  
25 sugar in the amino sugar containing solution having a pH of 2.0-5.0 in one or more of said compartments is present in a concentration of 15-40% by weight, preferably 20-40% by weight, most preferably at least 30% by weight, with the basis on the solution in each of said compartments,  
30 e.g. 15, 20, 25, 30, 35, and 40% by weight. Preferably, said amino sugar is N-acetylglucosamine (NAG).

The upper limit for the concentration for each amino sugar in the solution is determined by its solubility therein. The compartment comprising the amino sugar con-  
35 taining solution may also contain any organic acid or other pH stabilising agent in order to further stabilise the pH during sterilisation. The solutions of the diffe-

rent compartments have such respective pH values, concentrations and volumes that the finally prepared medical solution after mixing the solutions of the compartments has a pH that is substantially neutral, i.e. a pH between  
5 6.0 and 8.0, preferably about 7.4, and an amino sugar concentration between 0.2 and 15.0%, preferably 0.5-6.0%, e.g. 0.5-2.0% by weight, with the basis on the finally prepared solution.

The volume of each compartment, as well as the proportion between the compartments, is in practice not  
10 critical. Each compartment volume depends on the volume of constituent to be present therein. In the most preferred embodiment, the compartment which accommodates the pH adjusting and diluting solution is larger than the  
15 compartment which accommodates the amino sugar containing solution and is also the compartment in which the solution/solutions from the other compartments is/are mixed with the pH adjusting and diluting solution.

In a preferred embodiment the medicament to be prepared is a peritoneal dialysis solution containing N-  
20 acetylglucoseamine and having a pH of 7.4.

It should be noted that the decomposition pattern for an amino sugar solution during heat sterilisation follows specific Maillard reactions giving several  
25 different toxic decomposition products. The decomposition pattern differs for e.g. a glucose solution during heat sterilisation, wherein different decomposition products are formed. This difference is illustrated in Figs 4a - 4d, showing chromatograms when analysing 3-DG and 3,4-DGE  
30 in a NAG solution and in a glucose solution, respectively. The difference in degradation is likely due to that the NAG molecules contains groups that allows the Maillard reaction to take place and therefore create a large number of degradation products not seen in a  
35 glucose solution.

The term "amino sugar containing solution" used herein means a solution comprising one or more acetylated

or deacetylated amino sugars involved in the present invention chosen from N-acetylglucosamine (NAG), galactosamine, N-acetylgalactosamine, mannosamine, and N-acetylmannosamine in the form of monomers, oligomers and/or  
5 polymers thereof including chitin, and human glucosaminoglycans, as well as derivatives thereof. The most preferred amino sugar is N-acetylglucosamine (NAG). Thus, the acetylated or deacetylated amino sugars may be represented by only one of the amino sugars listed or by a  
10 combination thereof as well as derivatives thereof.

The term "derivatives thereof" used herein means derivatives of said amino sugars having the same or essentially the same ability to form cytotoxic degradation products during sterilisation.

15 The term "pH adjusting and diluting solution" used herein means a solution to be mixed with, e.g. acting as a receiving medium for, the amino sugar containing solution and at the same time a solution adjusting the pH of the solution after mixing with the amino sugar containing  
20 solution to essentially neutral, i.e. with a pH between for example 6.0 and 8.0, preferably about 7.4.

The term "low levels of cytotoxic degradation products" used herein means that the amount of degradation products from the amino sugars is so low in the medical  
25 solution prepared according to the present invention that it is not more toxic to cultured cells than dialysis solutions according to prior art.

The pH adjusting and diluting solution in the preferred embodiment contains pH adjusting agents, such as  
30 salts of inorganic acids, organic acids, alkalic substances etc. in a pharmaceutically stable range. Inorganic acids include hydrochloride acid etc., organic acids include lactic acid, malic acid, acetic acid, succinic acid, maleic acid, pyruvic acid, citric acid,  
35 gluconic acid, etc., and alkalic substances include sodium hydrate, sodium bicarbonate etc. Also, various amino acids can be used as a pH-adjusting agent.

After sterilisation the amino sugar containing solution is finally prepared for use by mixing it with the pH adjusting and diluting solution, optionally with solutions in other compartments of the container. The medical solution, preferably a peritoneal dialysis solution, thus obtained may also comprise different electrolyte ions, e.g. sodium, potassium, calcium, magnesium, chloride, lactate, and bicarbonate ions, in concentrations which are biocompatible and substantially isotonic. The electrolytes may be originally present in the pH adjusting and diluting solution, the amino sugar containing solution and/or another solution in one or more other compartments of the container, depending on their compatibility during sterilisation and storage, normally in the form of pharmaceutically acceptable salts. The amount of cations in a peritoneal dialysis solution ready for use is generally 110 to 140 mEq/ml of sodium ions, 0 to 0.05 mEq/l of potassium ions, 0 to 3 mEq/l of magnesium ions and 0 to 6 mEq/l of calcium ions. Preferably the amount of chloride ions is 80 to 144 mEq/l.

The peritoneal dialysis solution as a preferred embodiment of the medical solution according to the present invention may also comprise other physiologically compatible constituents, e.g. further osmotic agents, such as carbohydrates, preferably glucose, proteins and peptides, preferably albumin, as well as antioxidants, such as bisulphite.

The peritoneal dialysis solution of the present invention described above is applicable not only to continuous ambulatory peritoneal dialysis (CAPD) but also to intermittent peritoneal dialysis (IPD), continuous cyclic peritoneal dialysis (CCPD), and automated peritoneal dialysis (APD). Moreover, it contains low levels of cytotoxic degradation products from amino sugars.

The present invention also relates to a solution as such having the above defined characteristics.

The present invention also relates to a container containing the amino sugar containing solution in at least one compartment, wherein said solution has been sterilised and contains low levels of cytotoxic degradation products.

Further, the present invention relates to use of the solution according to the present invention for the manufacture of a medicament for peritoneal dialysis, wherein it is mixed with a sterilised pH-adjusting and diluting solution.

As stated above, the present invention also relates to a method of performing peritoneal dialysis, wherein said method comprises the introduction of said medicament for peritoneal dialysis into the peritoneal cavity of a patient.

In order to illustrate different embodiments of the present invention, containers having different compartment constructions containing the constituents for the preparation of a peritoneal dialysis solution will be described in the Examples below, as well as the composition of the solutions in each compartment. In the examples, N-acetylglucosamine (NAG) is used as amino sugar, either in one or two compartments of the container. The pH for the NAG containing solutions in each compartment varied between 2.0 and 5.0 before mixing and between 6.0 and 8.0 in the finally prepared medical solution.

#### Examples

##### Example 1

30	Compartment A	Volume	100 ml
		Sodium	0-140 mM
		NAG	300 g/l
	Compartment B	Volume	180 ml
		Sodium	0-140 mM
		NAG	300 g/l
35	Compartment C	Volume	1900 ml
		Sodium	0-140 mM
		Lactate	40 mM

13

Magnesium 0.25-0.75 mM

Calcium 0.9-2.0 mM

Final composition when the contents of compartments A+C  
are mixed:

5	Volume	2000 ml
	Sodium	0-140 mM
	NAG	15 g/l
	Lactate	38 mM
	Magnesium	0.24-0.71 mM
10	Calcium	0.85-1.9 mM

Final composition when the contents of compartments B+C  
are mixed:

	Volume	2080 ml
	Sodium	0-140 mM
15	NAG	26 g/l
	Lactate	36.5 mM
	Magnesium	0.22-0.68 mM
	Calcium	0.82-1.8 mM

Final composition when the contents of compartments A+B+C  
are mixed:

20	Volume	2180 ml
	Sodium	0-140 mM
	NAG	38.5 g/l
	Lactate	34.9 mM
25	Magnesium	0.21-0.65 mM
	Calcium	0.78-1.7 mM

### Example 2

30	Compartment A	Volume	100 ml
		Sodium	0-140 mM
		NAG	300 g/l
	Compartment B	Volume	180 ml
		Sodium	0-140 mM
		Glucose	500 g/l
35	Compartment C	Volume	1900 ml
		Sodium	0-140 mM
		Lactate	40 mM

14

Magnesium 0.25-0.75 mM

Calcium 0.9-2.0 mM

Final composition when the contents of compartments A+C  
are mixed:

5	Volume	2000 ml
	Sodium	0-140 mM
	NAG	15 g/l
	Glucose	0 g/l
	Lactate	38 mM
10	Magnesium	0.24-0.71 mM
	Calcium	0.86-1.9 mM

Final composition when the contents of compartments A+B+C  
are mixed:

	Volume	2100 ml
15	Sodium	0-140 mM
	NAG	14.3 g/l
	Glucose	23.8 g/l
	Lactate	36 mM
	Magnesium	0.23-0.68 mM
20	Calcium	0.81-1.8 mM

### Example 3

#### Compartment A

	Volume	60 ml
	Sodium	0-140 mM
	NAG	165 g/l
25	Glucose	330 g/l

#### Compartment B

	Volume	100 ml
	Sodium	0-140 mM
	NAG	165 g/l
	Glucose	330 g/l

#### 30 Compartment C

	Volume	1900 ml
	Sodium	0-140 mM
	Lactate	40 mM
	Magnesium	0.25-0.75 mM
	Calcium	0.9-2.0 mM

35 Final composition when the contents of compartments A+C  
are mixed:

Volume	1960 ml
--------	---------



15

Sodium	0-140 mM
NAG	5.1 g/l
Glucose	10.1 g/l
Lactate	38.8 mM
Magnesium	0.24-0.73 mM
Calcium	0.87-1.9 mM

5

Final composition when the contents of compartments B+C are mixed:

Volume	2000 ml
Sodium	0-140 mM
NAG	8.25 g/l
Glucose	16.5 g/l
Lactate	38.0 mM
Magnesium	0.24-0.71 mM
Calcium	0.86-1.9 mM

15

Final composition when the contents of compartments A+B+C are mixed:

Volume	2060 ml
Sodium	0-140 mM
NAG	12.8 g/l
Glucose	25.6 g/l
Lactate	37 mM
Magnesium	0.23-0.69 mM
Calcium	0.83-1.8 mM

#### 25 Example 4

##### Compartment A

Volume	1000 ml
NAG	10 g/l
Glucose	20 g/l
Magnesium	0.48-1.46 mM
Calcium	1.8-4.0 mM

30

##### Compartment B

Volume	1000 ml
Sodium	0-140 mM
Bicarbonate	165 g/l

Final composition when the contents of compartments A+B are mixed:

35

Volume	2000 ml
Sodium	0-140 mM

16

	NAG	5 g/l
	Glucose	10 g/l
	Bicarbonate	37.5 mM
	Lactate	2.5 mM
5	Magnesium	0.24-0.73 mM
	Calcium	0.9-2.0 mM

The invention has been described above with reference to preferred embodiments of the invention. A skilled person will recognise that further combinations are possible. Modifications which are apparent to a skilled person are intended to be incorporated within the scope of the invention, which is limited only by the appended claims.

15

## CLAIMS

1. A method for preparing a medical solution, comprising the steps of:

5 a) providing a solution comprising one or more acetylated or deacetylated amino sugars in at least one compartment of a container, said solution having a pH of 2.0-5.0, and

b) terminal sterilisation of said at least one  
10 compartment and the contents therein.

2. The method according to claim 1, wherein the pH is 2.5-3.5, preferably 3.0.

3. The method according to claim 1, wherein said one  
15 or more acetylated or deacetylated amino sugar/sugars is/are chosen from N-acetylglucosamine (NAG), galactosamine, N-acetylgalactosamine, mannosamine, and N-acetylmannosamine in the form of monomers, oligomers and/or polymers thereof including chitin, and human glucoseaminoglycans, as well as derivatives thereof.

20 4. Method according to any one of the previous claims, wherein said one or more acetylated or deacetylated amino sugar/sugars is/are present in a concentration of 15-40% by weight, preferably 20-40% by weight, most preferably at least 30% by weight, with the basis of the  
25 solution in said at least one compartment.

5. The method according to any one of the previous claims, wherein said one or more acetylated or deacetylated amino sugar/sugars is N-acetylglucosamine (NAG).

6. The method according to any one of the preceding  
30 claims, wherein the terminal sterilisation is heat sterilisation at a temperature of at least 100°C, preferably at 121°C, and/or radiation sterilisation.

7. The method according to any one of the preceding  
35 claims, wherein each compartment of the container is delimited from the other/others during the terminal sterilisation, and wherein the terminally sterilised solution containing one or more acetylated or deacetylat-

ed amino sugars is/are mixed with a terminally sterilised pH adjusting and diluting solution in at least one other terminally sterilised compartment of the container, thereby finally preparing the medical solution.

5           8. The method according to claim 7, wherein the pH in the finally prepared medical solution is 6.0-8.0, preferably 7.4.

          9. The method according to claim 7 or 8, wherein the concentration of acetylated or deacetylated amino sugar/-  
10   sugars in the finally prepared solution is/are 0.2-15.0% by weight, preferably 0.5-6.0% by weight.

          10. The method according to any one of the preceding claims, wherein physiologically compatible constituents in the form of carbohydrates, preferably glucose, pro-  
15   teins, peptides, and antioxidants are present in one or more of said compartments.

          11. The method according to any one of the preceding claims, wherein the medical solution prepared is a peritoneal dialysis solution.

20           12. A solution comprising one or more acetylated or deacetylated amino sugar/sugars and having a pH of 2.0-5.0, preferably 2.5-3.5, most preferably 3.0, wherein said solution is terminally sterilised and contains low levels of cytotoxic degradation products.

25           13. The solution according to claim 12, wherein said one or more acetylated or deacetylated amino sugar/sugars is/are present in a concentration of 15-40% by weight, preferably 20-40% by weight, most preferably at least 30% by weight.

30           14. The solution according to any one of claims 12 and 13, wherein the acetylated or deacetylated amino sugar/sugars is/are as defined in claim 3, and preferably is N-acetylglucosamine.

          15. A container comprising at least one compartment  
35   containing a solution according to any one of claims 12-14.

16. Use of a solution according to any one of claims 12-14 for the manufacture of a medicament for peritoneal dialysis, wherein it is mixed with a terminally sterilised pH adjusting and diluting solution.

1/6




Figure 1. Inhibition of cell growth in a solution containing 1.5% NAG.




Figure 2. The effect of increased NAG concentration from 1.5% (black bars) to 30% (grey bars) for three different pH values.

2/6





Figure 3. Fluorescence of heat sterilised NAG-containing solutions at different pH.

3/6


Figure 4a.






4/6

Figure 4b.




5/6

Figure 4c.



6/6

Figure 4d.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001920

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61J 1/00, A61M 1/28, B65D 81/32, A61K 9/08, A61K 31/70  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61J, A61M, B65D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Peritoneal Dialysis International, Volum 21, 2001, Andrezj Breborowicz et al, "Replacement of glucose with N-acetylglucosamine in peritoneal dialysis fluid-experimental study in rats", pages 3365-367, page 365, column 2, lines 24-36 --	1-16
Y	US 5536469 A (JONSSON ET AL), 16 July 1996 (16.07.1996), abstract, claims 1-78 --	1-16
A	WO 9706810 A1 (WU, GEORGE), 27 February 1997 (27.02.1997), abstract, page 4, line 22 - page 5, claim 1-8 --	1-16

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

19 February 2004

Date of mailing of the international search report

25-02-2004

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

MALIN SÖDERMAN/BS  
Telephone No. +46 8 78 2 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2003/001920

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9927885 A1 (GAMBRO AB), 10 June 1999 (10.06.1999), abstract, claims 1-7  -----  -----	1-16

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

24/12/2003

International application No.

PCT/SE 2003/001920

US	5536469	A	16/07/1996	DE	69230473 D,T	04/05/2000
				DK	668785 T	13/06/2000
				EP	0668785 A,B	30/08/1995
				SE	0668785 T3	
				EP	0951915 A	27/10/1999
				EP	1114645 A	11/07/2001
				EP	1114646 A	11/07/2001
				ES	2139608 T	16/02/2000
				JP	3250807 B	28/01/2002
				JP	7500992 T	02/02/1995
				SE	9103395 D	00/00/0000
				WO	9309820 A	27/05/1993
				DE	69312912 D,T	12/03/1998
				EP	0627998 A,B	14/12/1994
				ES	2107657 T	01/12/1997
				JP	7507016 T	03/08/1995
				SE	500633 C	01/08/1994
				SE	9200631 A	03/09/1993
				US	5563453 A	08/10/1996
				WO	9317895 A	26/09/1993
<hr/>						
WO	9706810	A1	27/02/1997	AT	218874 T	15/06/2002
				AU	697288 B	01/10/1998
				AU	6653396 A	12/03/1997
				AU	9825298 A	04/03/1999
				CA	2155910 A,C	12/02/1997
				CN	1195291 A	07/10/1998
				DE	69621819 D,T	02/01/2003
				DK	859621 T	23/09/2002
				EP	0859621 A,B	26/08/1998
				SE	0859621 T3	
				ES	2176476 T	01/12/2002
				IL	123196 A	17/09/2003
				JP	11511140 T	28/09/1999
				NO	980500 A	05/02/1998
				NZ	313953 A	27/04/2001
				PL	324891 A	22/06/1998
				PT	859621 T	29/11/2002
				RU	2158593 C	10/11/2000
				US	6083935 A	04/07/2000
<hr/>						
WO	9927885	A1	10/06/1999	AU	742793 B	10/01/2002
				AU	1515399 A	16/06/1999
				BR	9815055 A	30/04/2002
				CA	2311903 A	10/06/1999
				CN	1280481 T	17/01/2001
				EP	1035823 A	20/09/2000
				JP	2001524353 T	04/12/2001
				SE	512349 C	06/03/2000
				SE	9704386 A	29/05/1999